Related Experiment Videos
[Cellular and molecular therapy in severe combined immunodeficiencies]
F Porta1, F Candotti, A Arrighini
1Clinica Pediatrica, Università degli Studi di Brescia, Italia.
Summary
Severe combined immunodeficiencies (SCID) are fatal without treatment. Bone marrow transplants offer survival, with newer molecular therapies showing promise for enzyme deficiencies like adenosine-deaminase (ADA) deficiency.
Area of Science:
- Immunology
- Hematology
- Pediatric Medicine
Background:
- Severe combined immunodeficiencies (SCID) are life-threatening genetic disorders characterized by profound defects in cellular and humoral immunity.
- Patients typically present with early-onset, severe infections from various pathogens, necessitating urgent intervention.
- Limited availability of HLA-identical donors restricts allogeneic bone marrow transplantation (BMT) options.
Purpose of the Study:
- To review current strategies for managing SCID, including bone marrow transplantation (BMT) from various donor sources.
- To highlight the advancements in molecular therapy for specific SCID subtypes, such as adenosine-deaminase (ADA) deficiency.
Main Methods:
- Analysis of European multicenter data on bone marrow transplantation (BMT) outcomes for SCID patients.
- Description of T-cell purging techniques for HLA-non-identical donor BMT.
- Overview of molecular therapy using polyethylene glycol (PEG)-conjugated adenosine-deaminase (ADA) for ADA-SCID.
Main Results:
- Overall survival rates for HLA-identical BMT are 76%, compared to 56% for BMT from non-identical donors.
- Molecular therapy with PEG-ADA has shown success in reconstituting cellular and humoral immunity in children with ADA-SCID.
Conclusions:
- Bone marrow transplantation remains a critical treatment for SCID, with varying survival rates based on donor matching.
- Molecular therapy represents a promising alternative for specific SCID types, offering a viable treatment option when transplantation is not feasible.